Lotte Healthcare and Theragen Bio Form Partnership for Personalized Health Management

Lee Hoon-ki, CEO of Lotte Healthcare, and Hwang Tae-soon, CEO of Theragen Bio (from left in the photo), are posing for a commemorative photo at the joint investment contract ceremony.

[Asia Economy Reporter Chunhee Lee] Lotte Healthcare, a healthcare specialist company under Lotte Group, and Theragen Bio, a genome analysis service and AI-based new drug development company, have signed an investment and strategic partnership agreement to jointly promote business based on genome analysis services. The two companies plan to collaborate on genome testing service business and jointly pursue new business ventures.

The two companies intend to integrate Theragen Bio's genome testing services into Lotte Healthcare's personalized health management platform. Through the newly developed platform, they will provide personalized prescriptions such as health functional foods, diets, and exercise recommendations based on gene test results and individual health data using recommendation algorithms.

Lotte Healthcare is a corporation established in April with an investment of 70 billion KRW to exclusively handle the healthcare business, which Lotte Group has designated as a new growth industry. As its first project, Lotte Healthcare plans to launch a healthcare-specialized vertical commerce platform offering a total solution for personalized health management by the first half of next year. Through collaboration with medical institutions, the platform process will cover analysis, prescription, management, and compensation, aiming to provide products and services that allow individuals to scientifically understand their bodies and effectively manage their health.

Hwang Tae-soon, CEO of Theragen Bio, stated, “The partnership between the two companies is a case where a large corporation has invested in the research and development of a leading domestic genome company. We expect that through continuous joint research with the government and medical community, we will accelerate the establishment of medical scientific evidence and greatly contribute to job creation in the domestic and international genome testing markets as well as strengthening national competitiveness.”

This content was produced with the assistance of AI translation services.